UY38384A - Inhibidores de egfr de quinazolina novedosos - Google Patents

Inhibidores de egfr de quinazolina novedosos

Info

Publication number
UY38384A
UY38384A UY0001038384A UY38384A UY38384A UY 38384 A UY38384 A UY 38384A UY 0001038384 A UY0001038384 A UY 0001038384A UY 38384 A UY38384 A UY 38384A UY 38384 A UY38384 A UY 38384A
Authority
UY
Uruguay
Prior art keywords
egfr inhibitors
quinazoline egfr
new quinazoline
new
inhibitors
Prior art date
Application number
UY0001038384A
Other languages
English (en)
Inventor
V Chaturvedula Prasad
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of UY38384A publication Critical patent/UY38384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente documento describe una clase novedosa de inhibidores de EGFR de quinazolina. También se describen composiciones farmacéuticas de estos y un método para tratar cánceres
UY0001038384A 2018-09-21 2019-09-23 Inhibidores de egfr de quinazolina novedosos UY38384A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862734655P 2018-09-21 2018-09-21

Publications (1)

Publication Number Publication Date
UY38384A true UY38384A (es) 2020-04-30

Family

ID=69887926

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038384A UY38384A (es) 2018-09-21 2019-09-23 Inhibidores de egfr de quinazolina novedosos

Country Status (10)

Country Link
US (1) US20210353627A1 (es)
EP (1) EP3852762A4 (es)
JP (1) JP2022501344A (es)
KR (1) KR20210066841A (es)
CN (1) CN113056272A (es)
AR (1) AR116483A1 (es)
CA (1) CA3112198A1 (es)
TW (1) TW202023563A (es)
UY (1) UY38384A (es)
WO (1) WO2020061470A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201333A1 (en) 2020-11-11 2022-05-19 Bayer Aktiengesellschaft N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
WO2022105908A1 (zh) * 2020-11-23 2022-05-27 上海和誉生物医药科技有限公司 Egfr抑制剂及其制备方法与在药学上的应用
WO2022221227A1 (en) 2021-04-13 2022-10-20 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
WO2023213882A1 (en) 2022-05-04 2023-11-09 Bayer Aktiengesellschaft Irreversible mutegfr inhibitors
WO2024028316A1 (en) 2022-08-02 2024-02-08 Bayer Aktiengesellschaft 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
WO2004013091A2 (en) * 2002-08-01 2004-02-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
JP2007509059A (ja) * 2003-10-16 2007-04-12 カイロン コーポレイション 癌の処置のためのＲａｆキナーゼのインヒビターとしての、２，６−二置換キナゾリン、キノキサリン、キノリンおよびイソキノリン
US8426429B2 (en) * 2004-08-06 2013-04-23 Jansssen Pharmaceutica N.V. 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
KR20230145496A (ko) * 2016-11-17 2023-10-17 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
CN108299398B (zh) * 2018-04-27 2021-04-02 广州富瑞价值医疗健康产业有限公司 一种具有抗肿瘤活性含咔唑的喹唑啉衍生物及其制药用途

Also Published As

Publication number Publication date
JP2022501344A (ja) 2022-01-06
TW202023563A (zh) 2020-07-01
CN113056272A (zh) 2021-06-29
KR20210066841A (ko) 2021-06-07
CA3112198A1 (en) 2020-03-26
AR116483A1 (es) 2021-05-12
WO2020061470A1 (en) 2020-03-26
EP3852762A1 (en) 2021-07-28
EP3852762A4 (en) 2022-08-17
US20210353627A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
UY38384A (es) Inhibidores de egfr de quinazolina novedosos
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
UY37870A (es) Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
BR112016029662A2 (pt) compostos de heteroaril para inibição de quinase
BR112021024236A2 (pt) Proteínas multiespecíficas
CL2020003339A1 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
CY1124613T1 (el) Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
PH12017501879A1 (en) Methods for treating cancer
EA201892368A1 (ru) ИНГИБИТОРЫ ErbB И ИХ ПРИМЕНЕНИЕ
EA202091337A1 (ru) Ингибиторы гистонацетилтрансфераз семейства myst
BR112018005331A2 (pt) inibidores de pcna
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
EA201892051A1 (ru) Фармацевтические композиции для лечения злокачественного новообразования
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
BR112022001336A8 (pt) Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo
CO2020006542A2 (es) Profármacos de creatina, composiciones y métodos de uso de estos
BR112021008200A2 (pt) Composições e métodos para distúrbios de alfa-1-antitripsina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20240529